This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

 Previous Article  |  Next Article 

Hotlines established to help physicians deal with IGIV shortages

Due to physicians' recent diifficulties in obtaining Immune Globulin Intravenous (IGIV), the Food and Drug Administration (FDA) has asked drug manufacturers to establish an emergency reserve supply, according to the U.S. Department of Health and Human Services.

IGIV shortage may be caused by decreases in production, product recalls and a progressive increase in usage. The FDA is working closely with manufacturers to expedite lot release and to facilitate increased production and distribution.